MindBio Therapeutics Corp. (CSE: MBIO; Frankfurt: WF6; OTCQB: MBQIF) is advancing an artificial intelligence-driven voice analysis platform designed to detect drug and alcohol intoxication in real time. The company is targeting a rapidly expanding market for faster, scalable, and noninvasive impairment detection across workplace safety, healthcare, and public safety sectors. By leveraging speech as a diagnostic biomarker, MindBio is pursuing a differentiated approach to multisubstance intoxication detection within an evolving AI healthcare landscape that includes HeartFlow Inc. (NASDAQ: HTFL), Recursion Pharmaceuticals Inc. (NASDAQ: RXRX), Tempus AI Inc. (NASDAQ: TEM), and Butterfly Network Inc. (NYSE: BFLY).
As substance-use patterns evolve and the limitations of traditional testing methods become increasingly apparent, AI-enabled diagnostics are gaining momentum as a potential next-generation solution for real-time decision-making and risk management. MindBio is targeting large commercial opportunities spanning workplace compliance, telehealth, and consumer health applications. The company's voice-based platform is positioned within a broader transformation toward accessible, data-driven diagnostic technologies.
MindBio's AI prediction model uses over 50 million data points to predict alcohol intoxication with remarkable accuracy, using only the human voice. The company is developing an enterprise platform including Edge-AI kiosks that integrate bespoke hardware and software for the detection of drug and alcohol intoxication using the human voice and AI. These systems are designed for a range of enterprise environments, including the mining industry, aviation, construction, and law enforcement.
The full press release is available at https://ibn.fm/BZOb2. For more information about MindBio Therapeutics, visit their newsroom at https://ibn.fm/MBQIF.
